Sangamo Therapeutics (SGMO) Trading 0% Higher

Shares of Sangamo Therapeutics Inc (NASDAQ:SGMO) traded up 0% during mid-day trading on Wednesday . The company traded as high as $18.95 and last traded at $18.90. 2,238,611 shares were traded during trading, an increase of 4% from the average session volume of 2,144,692 shares. The stock had previously closed at $18.90.

A number of analysts have issued reports on the stock. ValuEngine upgraded shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday. BidaskClub lowered shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, March 27th. Wedbush reiterated a “hold” rating and set a $8.00 price target on shares of Sangamo Therapeutics in a research note on Tuesday, March 13th. Barclays reiterated a “buy” rating and set a $30.00 price target on shares of Sangamo Therapeutics in a research note on Sunday, February 25th. Finally, Jefferies Group reiterated a “buy” rating on shares of Sangamo Therapeutics in a research note on Friday, February 23rd. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $20.83.

How to Become a New Pot Stock Millionaire

The company has a current ratio of 5.54, a quick ratio of 5.54 and a debt-to-equity ratio of 0.13. The company has a market capitalization of $1,631.81, a price-to-earnings ratio of -25.00 and a beta of 2.80.

Sangamo Therapeutics (NASDAQ:SGMO) last released its earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.18) by $0.03. Sangamo Therapeutics had a negative net margin of 149.23% and a negative return on equity of 31.44%. The firm had revenue of $13.08 million for the quarter, compared to analyst estimates of $11.10 million. During the same period in the prior year, the firm earned ($0.14) earnings per share. The business’s quarterly revenue was up 46.6% compared to the same quarter last year. analysts forecast that Sangamo Therapeutics Inc will post -0.15 EPS for the current fiscal year.

In related news, Director Steven J. Mento sold 7,215 shares of the company’s stock in a transaction that occurred on Monday, April 2nd. The shares were sold at an average price of $18.40, for a total transaction of $132,756.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Curt A. Herberts III sold 15,000 shares of the company’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $20.59, for a total transaction of $308,850.00. Following the sale, the vice president now owns 29,625 shares in the company, valued at $609,978.75. The disclosure for this sale can be found here. Insiders have sold 89,896 shares of company stock worth $1,950,712 over the last 90 days. Insiders own 5.50% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the stock. Fred Alger Management Inc. purchased a new position in Sangamo Therapeutics in the fourth quarter valued at approximately $148,000. Xact Kapitalforvaltning AB purchased a new position in Sangamo Therapeutics in the fourth quarter valued at approximately $175,000. Great West Life Assurance Co. Can increased its stake in Sangamo Therapeutics by 150.3% in the third quarter. Great West Life Assurance Co. Can now owns 12,767 shares of the biopharmaceutical company’s stock valued at $182,000 after purchasing an additional 7,667 shares during the last quarter. Chicago Equity Partners LLC purchased a new position in Sangamo Therapeutics in the fourth quarter valued at approximately $192,000. Finally, Raymond James Financial Services Advisors Inc. purchased a new position in Sangamo Therapeutics in the third quarter valued at approximately $220,000. Hedge funds and other institutional investors own 64.68% of the company’s stock.

WARNING: “Sangamo Therapeutics (SGMO) Trading 0% Higher” was published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this article on another website, it was illegally stolen and reposted in violation of US & international copyright law. The legal version of this article can be viewed at https://www.tickerreport.com/banking-finance/3335347/sangamo-therapeutics-sgmo-trading-0-higher.html.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Somewhat Positive News Coverage Somewhat Unlikely to Impact Wintrust Financial  Stock Price
Somewhat Positive News Coverage Somewhat Unlikely to Impact Wintrust Financial Stock Price
SAGE Therapeutics  Receives Media Impact Score of 0.08
SAGE Therapeutics Receives Media Impact Score of 0.08
First Citizens BancShares  Given Daily Media Sentiment Rating of 0.22
First Citizens BancShares Given Daily Media Sentiment Rating of 0.22
International Game Technology  Receiving Somewhat Favorable Press Coverage, Accern Reports
International Game Technology Receiving Somewhat Favorable Press Coverage, Accern Reports
Acute Angle Cloud Tops 1-Day Volume of $7.13 Million
Acute Angle Cloud Tops 1-Day Volume of $7.13 Million
FuturXe  Price Tops $0.0093 on Exchanges
FuturXe Price Tops $0.0093 on Exchanges


© 2006-2018 Ticker Report. Google+.